Cardinal Health, Inc. filings document material events for a healthcare distribution and medical products company, including quarterly results, Regulation FD outlook updates and earnings presentation exhibits. The records tie financial reporting to segment performance, capital returns, debt reduction and corporate finance matters such as revolving credit agreements that support the commercial paper program.
Governance filings cover board composition, annual meeting voting results, director and officer transitions, and related compensation or succession disclosures. The company’s 8-K record also includes material definitive agreements, shareholder voting matters, financial covenants, exhibits and other capital-structure disclosures for Cardinal Health’s public-company profile.
Cardinal Health (CAH) reported fiscal 2027 first-quarter revenue of $67.5 billion, up 5% year over year, led by branded and specialty pharmaceutical sales growth from existing customers. GAAP operating earnings rose 13% to $753 million and diluted EPS increased 27% to $2.38; non-GAAP operating earnings were $1.0 billion, up 17%, and non-GAAP diluted EPS was $3.26, up 28%.
Pharma segment profit increased 17% to $783 million, while Global Medical Products and Distribution (GMPD) segment profit declined 28% to $33 million; GMPD revenue was flat at $3.2 billion. The company said tariff-related cost increases in GMPD had not been fully offset, and higher fuel and transportation costs tied to the Iran conflict affected operations. It noted uncertainty about proposed generic-drug tariffs of 100% beginning in 2028 and 200% beginning in 2029.
Net cash provided by operating activities was $1.398 billion. Cash and equivalents were $5.3 billion at September 30, 2026, and total long-term obligations were $8.8 billion. Cardinal Health deployed $500 million for common-share repurchases during the quarter under an accelerated share repurchase program.
Cardinal Health (CAH) reported first-quarter fiscal 2027 revenue of $67.5 billion, up 5% year over year, and raised its fiscal 2027 non-GAAP diluted EPS guidance to $12.80–$13.00 from $12.40–$12.60. GAAP diluted EPS was $2.38, up 27%, while non-GAAP diluted EPS was $3.26, up 28%; GAAP and non-GAAP operating earnings were $753 million and $1.0 billion, respectively.
Pharmaceutical and Specialty Solutions revenue rose 6% to $62.6 billion, and segment profit increased 17% to $783 million. Global Medical Products and Distribution segment profit declined 28% to $33 million, while Other segment profit rose 16% to $193 million. The company completed its $500 million share repurchase program during the quarter and entered a binding letter of intent to renew pharmaceutical distribution agreements with CVS Health.
Cardinal Health anticipates completing the AdaptHealth Diabetes Health business acquisition in Q3 of fiscal 2027. It also announced an additional $1.0 billion in uncommitted revolving credit facilities. Guidance incorporates expected diluted weighted-average shares of 231 million to 232 million, compared with prior guidance of approximately 233 million.
Cardinal Health (CAH) entered into a binding letter of intent with CVS Health to extend its pharmaceutical distribution agreements through June 30, 2032. The extension continues Cardinal Health’s current scope of distribution services.
Cardinal Health reaffirmed previously issued fiscal 2027 non-GAAP EPS guidance of $12.40 to $12.60. The company described this range as 13% to 15% growth based on adjusted fiscal 2026 results that exclude the fiscal 2026 benefit from an IEEPA tariff refund. It also reaffirmed long-term non-GAAP EPS growth guidance of 12% to 14%. Cardinal Health said further updates may be provided during its first-quarter earnings call on November 5, 2026.
Cardinal Health, Inc. (CAH) is soliciting shareholder votes for its 2026 virtual annual meeting, where investors will elect 11 directors, approve on an advisory basis named executive officer pay, and ratify Ernst & Young LLP as independent auditor for the year ending June 30, 2027.
The proxy details strong fiscal 2026 results, including broad-based profit growth across all five operating segments, double-digit gains in GAAP and non-GAAP operating earnings, and significant increases in operating cash flow and earnings per share. One-year total shareholder return was robust, and three-year return was substantially higher, reflecting execution on strategic priorities in Pharmaceutical and Specialty Solutions, Global Medical Products and Distribution, and growth businesses such as Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Logistics.
The Board highlights an independent Chair structure, committee-only independent membership, enhanced enterprise risk management oversight through the Risk Oversight Committee, and an extensive shareholder engagement program. Recent board refreshment, leadership transitions, and a structured evaluation and education process are emphasized as key elements supporting long-term strategy, risk oversight, and sustainable value creation.
CARDINAL HEALTH INC (CAH) reported that Chief Accounting Officer Mary C. Scherer sold a total of 2,302 Common Shares on 2026-08-19 in open market or private transactions. The sales occurred in two tranches: 100 shares at $237.40 per share and 2,202 shares at $237.39 per share. The filing does not state her share holdings after these transactions, and the Rule 10b5-1 checkbox was left unchecked.
CARDINAL HEALTH INC (CAH) reported that Chief Executive Officer Jason M. Hollar sold an aggregate of 124,529 Common Shares in 10 open-market or private transactions on August 18–19, 2026. The reported weighted average sale prices ranged from approximately $232.75 to $238.07 per share, with each line item reflecting multiple trades within the stated price ranges.
CARDINAL HEALTH INC (CAH) reported that Stephen M. Mason, CEO of the Global Medical Products & Distribution segment, sold a total of 35,000 Common Shares on 2026-08-18 in four open-market transactions. The weighted average sale prices ranged from $234.07 to $237.67 per share, with all shares held directly. The Rule 10b5-1 trading-plan checkbox was not marked as applicable.
CARDINAL HEALTH INC (CAH) executive Deborah Weitzman, CEO of the Pharmaceutical and Specialty Solutions (PSS) segment, reported selling a total of 7,354 Common Shares on August 18, 2026 in three open-market transactions. The sales covered 6,665 shares at a weighted average price of $235.30 (price range $235.17–$236.02), 408 shares at a weighted average price of $236.59 (range $236.24–$237.143), and 281 shares at a weighted average price of $237.44 (range $237.2615–$237.6285). All holdings are reported as directly owned.
CARDINAL HEALTH INC (CAH) reported that Chief Financial Officer Aaron E. Alt sold a total of 42,000 Common Shares on August 18, 2026 in open-market or private transactions. The sales were executed in four blocks at weighted average prices between $234.55 and $237.26, with each price representing a weighted average of multiple trades within stated intraday ranges.